Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

The notice does not affect business operations or SEC reporting obligations and does not trigger default under material agreements.

Rhea-AI Summary

Annovis Bio (NYSE: ANVS) received a continued-listing deficiency notice from the New York Stock Exchange on October 29, 2026.

Its 30-trading-day average market capitalization was approximately $48.4 million as of October 28, while its last reported stockholders’ deficit was approximately $(4.3) million as of June 30. The applicable standard requires action when average market capitalization and stockholders’ equity are both below $50 million. Annovis plans to submit a compliance plan within 45 days of the notice, targeting conformity within 9 months of receipt. The notice has no immediate listing impact. Continued listing during the cure period depends on NYSE acceptance of the plan and compliance with it and other listing standards; failure could lead to suspension and delisting.

3 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Minor pointThe notice has no immediate impact on the common stock’s listing.
• Minor pointBusiness operations and SEC reporting obligations are unaffected by the notice.
• Minor pointThe notice causes no event of default under material debt or other agreements.

Negative

• Moderate pointListing deficiency reflects approximately $48.4 million average market capitalization and approximately $(4.3) million stockholders’ deficit.
• Minor point. Forward-looking: it has not happened yet and may not happen.Compliance plan must be submitted within 45 days of the notice and requires NYSE acceptance.
• Minor point. Forward-looking: it has not happened yet and may not happen.9-month cure period requires compliance with the plan and other listing standards to avoid suspension and delisting.
• Minor point. Forward-looking: it has not happened yet and may not happen.Accelerated delisting is possible at abnormally low trading prices; NYSE generally views prices below $0.10 this way.

News Explained

The NYSE will add a BC designation to Annovis’s common-stock ticker to mark that it is below continued-listing criteria; the marker will be removed once the company regains compliance.

Key Figures

Listing-standard thresholds: <$50 million each 30-day average market capitalization: $48.4 million Stockholders’ deficit: $(4.3) million +3 more

Listing-standard thresholds

<$50 million each

NYSE continued-listing criteria for market capitalization and stockholders’ equity

30-day average market capitalization

$48.4 million

As of October 28, 2026; NYSE notice measurement

Stockholders’ deficit

$(4.3) million

Last reported as of June 30, 2026

Plan submission deadline

45 days

After receipt of the NYSE notice

Conformity period

9 months

Period to regain compliance after receipt of the notice

Abnormally low trading price threshold

$0.10

Price below which the NYSE generally views trading as abnormally low

Key Terms

stockholders’ deficit, cure period

2 terms

stockholders’ deficit financial

"the Company’s last reported stockholders’ deficit as of June 30, 2026"

Stockholders’ deficit is the situation where a company’s total liabilities exceed its total assets, so the book value attributed to shareholders is negative. Think of it like a household with more outstanding debts than the value of its house and possessions—this can signal past losses or aggressive payouts and raises the risk that shareholders may be wiped out, diluted, or face difficulty when the company needs new financing. Investors watch it as a warning about solvency and long‑term financial health.

cure period regulatory

"will continue to be listed and traded on the NYSE during the cure period"

A cure period is a set amount of time given to a borrower, counterparty, or contracting party to fix a missed payment, breach, or other problem before more serious consequences—like penalties, higher interest, or contract termination—kick in. For investors, it matters because it creates a short grace window that can prevent immediate losses and influence the timing and likelihood of recovery; think of it like a few extra days to pay a bill before a service is cut off.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on October 29, 2026, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million.

The Notice does not affect the Company’s business operations or its reporting obligations with the Securities and Exchange Commission, and it does not conflict with or cause an event of default under any of the Company’s material debt or other agreements.

As set forth in the Notice, as of October 28, 2026, the 30 trading-day average market capitalization of the Company was approximately $48.4 million and the Company’s last reported stockholders’ deficit as of June 30, 2026 was approximately $(4.3) million.

The Company has notified the NYSE that it will submit a plan within 45 days of the Notice advising the NYSE of definitive action it has taken, or is taking, to bring it into conformity with Section 802.01B within 9 months of receipt of the Notice. The NYSE will review the Company’s plan and, within 45 days, make a determination as to whether the Company has made a reasonable demonstration of its ability to come into conformity with Section 802.01B within 9 months. If the Company’s plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings. If the NYSE accepts the Company’s plan, the Company’s common stock will continue to be listed and traded on the NYSE during the cure period, subject to the Company’s compliance with the plan and other continued listing standards. The NYSE will review the Company on a semi-annual basis to confirm compliance with the plan. If the Company fails to comply with the plan or does not meet continued listing standards at the end of the 9-month cure period, it will be subject to the prompt initiation of NYSE suspension and delisting procedures. The NYSE may take accelerated delisting action in the event the Company’s common stock trades at levels viewed to be abnormally low. The NYSE generally views trading below a price of $0.10 to be abnormally low.

The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be “ANVS”, subject to the Company’s continued compliance with the plan and other listing requirements of the NYSE. However, the common stock trading symbol will have an added designation of “.BC” to indicate that the status of the common stock is below criteria with the NYSE continued listing standards. The “.BC” indicator will be removed at such time as the Company regains compliance.

Cautionary Note Regarding Forward-Looking Statements

This press release contains, and oral statements made from time to time by our representatives may contain, “forward-looking statements.” Forward-looking statements include statements identified by words such as “could,” “may,” “might,” “will,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the Company’s ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSE’s acceptance of such plan; the Company’s ability to execute such plan and to continue to comply with applicable listing standards within the available cure period; risks arising from the potential suspension of trading of the Company’s common stock on the NYSE; regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Any forward-looking statement made in this report speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

About Annovis Bio

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Annovis Bio receive an NYSE continued-listing notice?

Annovis fell below the $50 million thresholds for both its 30-trading-day average market capitalization and stockholders’ equity. Average market capitalization was approximately $48.4 million as of October 28, 2026, and its last reported stockholders’ deficit was approximately $(4.3) million as of June 30, 2026.

What is Annovis Bio’s deadline to address its NYSE listing deficiency?

Annovis plans to submit a compliance plan within 45 days of the October 29, 2026 notice, outlining actions to regain conformity within 9 months of receipt. Continued listing during the cure period depends on NYSE acceptance of the plan and compliance with it and other listing standards.

How will the NYSE review Annovis Bio’s compliance plan?

The NYSE will review the plan and determine within 45 days whether Annovis has reasonably demonstrated its ability to regain conformity within 9 months. If accepted, the NYSE will review compliance with the plan on a semi-annual basis. An untimely or rejected plan will trigger delisting proceedings.

What does the .BC designation on Annovis Bio’s trading symbol mean?

The added .BC designation indicates that Annovis common stock is below the NYSE’s continued-listing criteria. The indicator will be removed when the company regains compliance.